Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 2,561 Shares of Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 2,561 shares of the stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $90.14, for a total transaction of $230,848.54. Following the completion of the sale, the executive vice president owned 29,276 shares of the company’s stock, valued at approximately $2,638,938.64. This represents a 8.04% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.03, for a total transaction of $274,051.32.
• On Thursday, November 12th, Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.56, for a total transaction of $1,605,085.44.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.54, for a total transaction of $9,118,555.02.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $92.48 on Friday. The company has a market capitalization of $5.21 billion, a price-to-earnings ratio of -23.18 and a beta of 1.47. Dianthus Therapeutics, Inc. has a 52-week low of $34.29 and a 52-week high of $117.88. The company has a 50-day simple moving average of $88.77 and a two-hundred day simple moving average of $86.36.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Wednesday, November 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.94) by $0.13. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. The firm had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $0.46 million. On average, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -3.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently modified their holdings of DNTH. BlackRock Inc. purchased a new position in Dianthus Therapeutics in the second quarter valued at approximately $401,990,000. Wellington Management Group LLP raised its stake in shares of Dianthus Therapeutics by 24.4% in the second quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after buying an additional 634,099 shares during the period. ABS Investment Management LLC purchased a new position in shares of Dianthus Therapeutics during the 2nd quarter valued at $194,960,000. Assenagon Asset Management S.A. lifted its position in shares of Dianthus Therapeutics by 160.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after buying an additional 451,597 shares during the last quarter. Finally, Jennison Associates LLC bought a new position in shares of Dianthus Therapeutics during the 1st quarter worth $40,713,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on DNTH. Citigroup assumed coverage on Dianthus Therapeutics in a report on Friday, September 4th. They set a “buy” rating and a $156.00 price target on the stock. Raymond James Financial restated a “strong-buy” rating and issued a $134.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, November 5th. Truist Financial raised their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Roth Capital assumed coverage on Dianthus Therapeutics in a research note on Tuesday, October 27th. They set a “buy” rating and a $113.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $158.00 target price on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and a consensus target price of $128.77.

Trending Headlines about Dianthus Therapeutics

Here are a few of the latest headlines about DNTH:

• Positive Sentiment: HC Wainwright was reported to have a bullish estimate for Dianthus’s FY2026 earnings, although the available report does not provide the estimate or its reasoning. Article: HC Wainwright Has Bullish Estimate for DNTH FY2026 Earnings
• Positive Sentiment: The company’s latest reported quarter beat analyst expectations for both adjusted loss per share and revenue, offering a supportive backdrop. Dianthus Therapeutics company information
• Negative Sentiment: EVP Ryan Savitz sold a combined 124,042 shares in transactions from November 9–12, worth about $11.2 million. The sales represent a significant reduction in his reported stake and could unsettle investors, though the reports do not give a reason for the transactions. Article: Dianthus Therapeutics EVP Sells 17,724 Shares of Stock

About Dianthus Therapeutics

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company’s research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.